Preview

Синдром Прадера-Вилли: новые возможности в лечении детей

https://doi.org/10.14341/probl201359433-40

Полный текст:

Аннотация

Синдром Прадера-Вилли (СПВ) представляет собой генетическое заболевание, главными симптомами которого являются тяжелая гиперфагия, приводящая к выраженному ожирению, задержка роста, характерные внешние особенности, сложности в обучении, поведенческие и психиатрические проблемы. В настоящее время единственным эффективным средством лечения СПВ, значительно улучшающим качество жизни пациентов, является рекомбинантный гормон роста (р-ГР). Проведен анализ многочисленных положительных эффектов и возможных рисков терапии р-ГР при СПВ.

Об авторах

E Bogova



N Volevodz



Список литературы

1. McCandless S.E. Clinical report-health supervision for Children with Prader-Willi Syndrome, the Committee on Genetics. Pediatrics 2011; 127: 1: 195-204.

2. Butler M.G., Thompson T. Prader-Willi syndrome: clinical and genetic findings. Endocrinologist 2000; 10: 3S-16S.

3. Whittington J.E., Holland A.J., Webb T., Butler J., Clarke D., Boer H. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J Med Genet 2001; 38: 792-798.

4. Vogels A., Van Den Ende J., Keymolen K., Vogels A., Van Den Ende J., Keymolen K., Mortier G., Devriendt K., Legius E., Fryns J.P. Minimum prevalence, birth incidence and cause of death for Prader-Willi syndrome in Flanders. Eur J Hum Genet 2004; 12: 3: 238-240; 38: 11: 792-798.

5. Driscoll D.J., Schwartz S., Cassidy S.B. Prader-Willi syndrome. Genet Med 2012; 14: 1: 10-26.

6. Nixon G.M., Brouillette R.T. Sleep and breathing in Prader-Willi syndrome. Pediat Pulmonol 2002; 34: 209-217.

7. Williams K., Scheimann A., Sutton V., Hayslett E., Glaze D.G. Sleepiness and sleep disordered breathing in Prader-Willi syndrome: relationship to genotype, growth hormone therapy, and body composition. J Clin Sleep Med 2008; 4: 2: 111-118.

8. Tauber M., Diene G., Molinas C., Hebert M. A review of 64 cases of death in children with Prader-Willi syndrome (PWS). Am J Med Genet A 2008; 46: 881-887.

9. Butler M.G., Meaney F.J. Standards for Selected Anthropometric Measurements in Prader-Willi Syndrome. Pediatrics 1991; 88: 4: 853-860.

10. Burman P., Ritzen E.M., Lindgren A.C. Endocrine dysfunction in Prader-Willi syndrome: a review with special reference toGH. Endocrinol Rev 2001; 22: 787-799.

11. Wollmann H.A., Schultz U., Grauer M.L., Ranke M.B. Reference values for height and weight in Prader-Willi syndrome based on 315 patients. Eur J Pediat 1998; 157: 634-642.

12. Hauffa B.P., Schlippe G., Roos M., Gillessen-Kaesbach G., Gasser T. Spontaneous growth in German children and adolescents with genetically confirmed Prader-Willi syndrome. Acta Paediat 2000; 89: 1302-1311.

13. Greenswag L.R. Adults with Prader-Willi syndrome: a survey of 232 cases. Dev Med Child Neurol 1987; 29: 145-152.

14. Costeff H., Holm V.A., Ruvalcaba R., Shaver J. Growth hormone secretion in Prader-Willi syndrome. Acta Paediat Scand 1990; 79: 11: 1059-1062.

15. Angulo M., Castro-Magana M., Uy J. Pituitary evaluation and growth hormone treatment in Prader-Willi syndrome. J Pediat Endocrinol 1991; 4: 167-173.

16. Lee P.D.K., Hwu K., Brown B.T., Greenberg F., Klish W.J. Endocrine investigations in children with Prader-Willi syndrome. Dysmorphol Clin Genet 1992; 6: 27-28.

17. Kokkoris P., Pi-Sunyer F.X. Obesity and endocrine disease. Endocrinol Metabol Clin North Am 2003; 32: 4: 895-914.

18. Angulo M., Castro-Magana M., Mazur B., Canas J.A., Vitollo P.M., Sarrantonio M. Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome. J Pediat Endocrinol Metabol 1996; 9: 393-400.

19. Grosso S., Cioni M., Buoni S., Peruzzi L., Pucci L., Berardi R. Growth hormone secretion in Prader-Willi syndrome. J Endocrinol Inv 1998; 21: 418-422.

20. Grugni G., Guzzaloni G., Moro D., Bettio D., De Medici C., Morabito F. Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostimine and administration in the Prader-Willi syndrome. Clin Endocrinol (Oxford) 1998; 48: 769-775.

21. Thacker M.J., Hainline B., St Dennis-Feezle L., Johnson N.B., Pescovitz O.H. Growth failure in Prader-Willi syndrome is secondary to growth hormone deficiency. Hormon Res 1998; 49: 216-220.

22. Corrias A., Bellone J., Beccaria L., Bosio L., Trifiro G., Livieri C., Ragusa L., Salvatoni A., Andreo M., Ciampalini P., Tonini G., Crino A. GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology. J Endocrinol Inv 2000; 23: 84-89.

23. Grugni G., Guzzaloni G., Morabito F. Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome. J Endocrinol Inv 2001; 24: 340-348.

24. Swaab D.F. Prader-Willi syndrome and the hypothalamus. Acta Paediat 1997; Suppl 423: 50-54.

25. Diene G., Mimoun E., Feigerlova E., Caula S., Molinas C., Grandjean H., Tauber M. Endocrine disorders in children with Prader-Willi syndrome-data from 142 children of the French database. Hormon Res Paediat 2010; 74: 2: 121-128.

26. Dong-Kyu Jin. Endocrine problems in children with Prader-Willi syndrome: special review on associated genetic aspects and early growth hormone treatment. Korean J Pediat 2012; 55: 7: 224-231.

27. Eiholzer U., Gisin R., Weinmann C., Kriemler S., Steinert H., Torresani T., Zachmann M., Prader A. Treatment with human growth hormone in patients with Prader-Labhart-Willi syndrome reduces body fat and increases muscle mass and physical performance. Eur J Pediatr 1998; 157: 5: 368-377.

28. Miller L., Angulo M., Price D., Taneja S. MR of the pituitary in patients with Prader-Willi syndrome: size determination and imaging findings. Pediat Radiol 1996; 26: 43-47.

29. Iughetti L., Bosio L., Corrias A., Gargantini L., Ragusa L., Livieri C., Predieri B., Bruzzi P., Caselli G., Grugni G. Pituitary height and neuroradiological alterations in patients with Prader-Labhart-Willi syndrome. Eur J Pediat 2008; 167: 701-702.

30. Chen C., Visootsak J., Dills S., Graham J.M. Prader-Willi syndrome: an update and review for the primary pediatrician. Clin Pediatr (Phila) 2007; 46: 7: 580-591.

31. Butler M.G. Prader-Willi syndrome: current understanding of cause and diagnosis. Am J Med Genet 1990; 35: 3: 319-332.

32. Meaney F.J., Butler M.G. Characterization of obesity in the Prader-Labhardt-Willi syndrome: fatness patterning. Med Anthropol Quart 1989; 3: 294-305.

33. Brambilla P., Bosio L., Manzoni P., Pietrobelli A., Beccaria L., Chiumello G. Peculiar body composition in patients with Prader-Labhart-Willi syndrome. Am J Clin Nutr 1997; 65: 1369-1374.

34. Eiholzer U., Blum W.F., Molinari L. Body fat determined by skin-fold measurements is elevated despite underweight in infants with Prader-Labhart-Willi syndrome. J Pediatr 1999; 134: 222-225.

35. Lindgren A.C., Hagenas L., Muller J., Blichfeldt S., Rosenborg M., Brismar T., Ritzén E.M. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably. Acta Pediatr 1998; 87: 28-31.

36. Carrel A.L., Myers S.E., Whitman B.Y., Allen D.B. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metabol 2002; 87: 4: 1581-1585.

37. Lee P.D.K., Wilson D.M., Hintz R.L., Rosenfield R.G. Growth hormone treatment of short stature in Prader-Willi syndrome. J Pediatr Endocrinol 1987; 2: 31-34.

38. Carrel A.L., Myers S.E., Whitman B.Y., Allen D.B. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study. J Pediatr 1999; 134: 215-221.

39. Lindgren A.C., Ritzen E.M. Five years of growth hormone treatment in children with Prader-Willi syndrome. Swedish National Growth Hormone Advisory Group. Acta Paediat 1999; 88: 433: Suppl: 109-111.

40. Eiholzer U., L'Allemand D. Growth hormone normalises height, prediction of final height and hand length in children with Prader-Willi syndrome after 4 years of therapy. Hormon Res 2000.

41. Tauber M. Effects of growth hormone treatment in children presenting with Prader-Willi syndrome: the KIGS experience. In: Growth hormone therapy in Pediatrics-20 years of KIGS. Eds. M.B. Ranke, D.A. Price, E.O. Reiter. Basel/Karger 2007; 377-387.

42. Angulo M., Castro-Magana M., Lamerson M., Arguello R., Accacha S., Khan A. Final adult height in children with Prader-Willi syndrome with and without human growth hormone treatment. Am J Med Genet A 2007; 143: 1456-1461.

43. Eiholzer U., l'Allemand D. Growth hormone normalizes height, prediction of final height and hand length in children with Prader-Willi syndrome after 4 years of therapy. Hormon Res 2000; 53: 185-192.

44. Myers S.E., Carrel A.L., Whitman B.Y., Allen D.B. Sustained benefi t after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. J Pediatr 2000; 137: 1: 42-49.

45. Eiholzer U., Meinhardt U., Gallo C., Schlumpf M., Rousson V., L'Allemand D. Association between foot growth and musculoskeletal loading in children with Prader-Willi syndrome before and during growth hormone treatment. J Pediatr 2009; 154: 2: 225-229.

46. Lindgren A.C., Hellstrom L.G., Ritzen E.M., Milerad J. Growth hormone treatment increases CO(2) response, ventilation and central inspiratory drive in children with Prader-Willi syndrome. Eur J Pediat 1999; 158: 11: 936-940.

47. Carrel A.L., Myers S.E., Whitman B.Y., Allen D.B. Prader-Willi syndrome: the effect of growth hormone on childhood body composition. Endocrinologist 2000; 10: 4: 3S-49S.

48. Lee P.D. Effects of growth hormone treatment in children with Prader-Willi syndrome. Growth Hormon IGF Res 2000; Suppl B: 75-79.

49. Eiholzer U., L'Allemand D, Inge van der Sluis, Steinert H., Gasser T., Kenneth E. Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy. Hormon Res 2000; 53: 200-206.

50. Eiholzer U. Prader-Willi Syndrome: Effects of Human Growth Hormone Treatment. Ed. M.O. Savage. Endocrine Development, Vol. 3. Zurich: Karger 2001.

51. Eiholzer U., L'Allemand D., Schlumpf M., Rousson V., Gasser T., Fusch C. Growth hormone and body composition in children younger than 2 years with Prader-Willi syndrome. J Pediat 2004; 144: 6: 753-758.

52. Whitman B., Carrel A., Bekx T., Weber C., Allen D., Myers S. Growth hormone improves body composition and motor development in infants with Prader-Willi syndrome after six months. J Pediat Endocrinol Metabol 2004; 17: 4: 591-600.

53. Carrel A.L., Moerchen V., Myers S.E., Bekx M.T., Whitman B.Y., Allen D.B. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J Pediatr 2004; 145: 744-749.

54. Festen D.A., de Lind van Wijngaarden R., van Eekelen M., Otten B.J., Wit J.M., Duivenvoorden H.J. et al. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome. Clin Endocrinol (Oxford) 2008; 69: 443-451.

55. Haqq A.M., Stadler D.D., Jackson R.H., Rosenfeld R.G., Purnell J.Q., LaFranchi S.H. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J Clin Endocrinol Metabol 2003; 88: 5: 2206-2212.

56. Eiholzer U., Stutz K., Weinmann C., Torresani T., Molinari L., Prader A. Low insulin, IGF-I and IGFBP-3 levels in children with Prader-Labhart-Willi syndrome. Eur J Pediat 1998; 157: 890-893.

57. Carrel A.L., Myers S.E., Whitman B.Y., Eickhoff J., Allen D.B. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome. J Clin Endocrinol Metabol 2010; 95: 3: 1131-1136.

58. National Institute for Health & Clinical Excellence Guideline. Human growth hormone (somatropin) for the treatment of growth failure in children. May 2010.

59. Goldstone A.P., Holland A.J., Hauffa B.P., Hokken-Koelega A.C., Tauber M. Speakers contributors at the second expert meeting of the comprehensive care of patients with PWS. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Ednocrinol Metabol 2008; 93: 4183-4197.

60. But W.M., Huen K.F., Lee C.Y., Lam Y.Y., Tse W.Y., Yu An C.M. Update on the Indications of Growth Hormone Treatment under Hospital Authority in Hong Kong HK. J Paediat (New Series) 2012; 17: 208-216.

61. Deal C.L., Tony M., Höybye C., Allen D.B., Tauber M., Christiansen J.S. The 2011 GH in PWS Clinical Care Guidelines Workshop Participants Growth Hormone Research Society Workshop Summary: Consensus Guidelines for Recombinant Human Growth Hormone Therapy in Prader-Willi Syndrome, J Clin Endocrinol Metabol 2013.

62. Guidelines for the Pharmaceutical Benefits Scheme Growth Hormone Program. Australian Government, Department of Health and Aging, September 2010.

63. Bakker B., Maneatis T., Lippe B. Sudden death in Prader-Willi syndrome: brief review of five additional cases. Eds. U. Eiholzer et al. Deaths in childrenwith Prader-Willi syndrome. A contribution to the debate about the safety of growth hormone treatment in children with PWS (Hormon Res 2005; 63: 33-39). Hormon Res 2007; 67: 4: 203-204.

64. Cabrol S., Perin L., Colle M., Coutant R., Jesuran-Perelroizen M., Le Bouc Y., Czernichow P. Evolution of IGF-1 in children born small for gestational age andwith growth retardation, treated by growth hormone adapted to IGF-1 levels after 1 year. Hormon Res Paediat 2011; 76: 6: 419-427.

65. Butler M.G., Lee P.D.K., Barbara Y. Whitman management of Prader-Willi Syndrome. 3-rd Ed. Spring Sci Bus Med Inc (New York) 2006.

66. de Lind van Wijngaarden R.F., de Klerk L.W., Festen D.A., Duivenvoorden H.J., Otten B.J., Hokken-Koelega A.C. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome. J Clin Endocrinol Metabol 2009; 94: 4: 1274-1280.

67. Lindgren A.C., Hagenas L., Ritzen E.M. In collaboration with the Swedish National Growth Hormone Advisory Group. Growth hormone treatment of children with Prader-Willi syndrome: effects on glucose and insulin homeostasis. Hormon Res 1999; 51: 157-161.

68. Zipf W.B. Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hormone therapy. Acta Paediat 1999; 88: Suppl 433: 115-117.


Для цитирования:


., . Синдром Прадера-Вилли: новые возможности в лечении детей. Проблемы Эндокринологии. 2013;59(4):33-40. https://doi.org/10.14341/probl201359433-40

For citation:


Bogova E.A., Volevodz N.N. Prader-Willi syndrome: new possibilities for its treatment in the children. Problems of Endocrinology. 2013;59(4):33-40. (In Russ.) https://doi.org/10.14341/probl201359433-40

Просмотров: 60


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)